Companies › GSK
86 active drug programs in 397 registered trials: 138 Phase 2, 124 Phase 1, 97 Phase 3, 38 Phase 4; Infectious disease, Oncology, Respiratory, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| rMenB+OMV NZ Meningococcal serogroup B vaccine containing recombinant meningococcal protein and outer m | – | Phase 4 | Meningitis, Meningococcal | Feb 2027 |
| Depemokimab Interleukin-5 inhibitor | IL5 | Phase 4 | Nasal Polyps; Eosinophilic Granulomatosis With Polyangiitis; Asthma; Hypereosinophilic Syndrome … | Mar 2027 |
| Umeclidinium Muscarinic acetylcholine receptor M3 antagonist | CHRM3 | Phase 4 | Asthma; COPD (Chronic Obstructive Pulmonary Disease); Chronic Obstructive Pulmonary Disease (COPD) | Jun 2027 |
| Belimumab Tumor necrosis factor ligand superfamily member 13B inhibitor | TNFSF13B | Phase 4 | Systemic Lupus Erythematosus; Lung Diseases, Interstitial; Connective Tissue Diseases; Systemic Sclerosis Associated Interstitial Lung Disease … | Jun 2027 |
| Varicella Zoster Virus Envelope Glycoprotein E Envelope glycoprotein E vaccine antigen | – | Phase 4 | Herpes Zoster; RZV Vaccine (Shingrix ®); Varicella Zoster Virus Infection; Autoimmune Rheumatic Diseases … | Aug 2027 |
| Mepolizumab Interleukin-5 inhibitor | IL5 | Phase 4 | Asthma; Chronic Rhinosinusitis with Nasal Polyps; Chronic Rhinosinusitis With Nasal Polyps; Nasal Polyps … | Jun 2028 |
| Belrestotug GITR agonist antibody | TNFRSF18 | Phase 3 | Lung Cancer, Non-Small Cell; Neoplasms, Head and Neck; Neoplasms | Nov 2026 |
| Dostarlimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Lung Cancer, Non-Small Cell; Neoplasms, Head and Neck; Colonic Neoplasms; Neoplasms, Colon … | Nov 2026 |
| Investigational varicella vaccine (VNS Vaccine) Live attenuated varicella vaccine | – | Phase 3 | Chickenpox | Nov 2026 |
| dTpa vaccine (Boostrix) Inactivated bacterial antigen vaccine against diphtheria, tetanus, and acellular pertussis | – | Phase 3 | Diphtheria-Tetanus-acellular Pertussis Vaccines | Nov 2026 |
| HFA-152a hydrofluoroalkane propellant | – | Phase 3 | Asthma | Dec 2026 |
| Niraparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Neoplasms, Breast; Ovarian Neoplasms; Neoplasms | Dec 2026 |
| Belantamab mafodotin Tumor necrosis factor receptor superfamily member 17 binding agent; Tubulin inhibitor | TNFRSF17, Tubulin | Phase 3 | Multiple Myeloma; Amyloidosis; Plasma Cell Myeloma; Myeloma Multiple … | Dec 2026 |
| RSVPreF3 OA investigational vaccine Respiratory syncytial virus (RSV) vaccine containing RSV fusion (F) protein in prefusion c | – | Phase 3 | Respiratory Syncytial Virus Infections | Dec 2026 |
| Fostemsavir Envelope polyprotein GP160 inhibitor | INSTI, GP120, CD4 | Phase 3 | HIV Infections; HIV-1-infection; Human Immunodeficiency Virus (HIV); HIV Infections With Multi Drug Resistant Virus | Jan 2027 |
| FF/UMEC/VI Inhaled corticosteroid/muscarinic antagonist/long-acting beta-2 agonist combination | CHRM3, ADRB2 | Phase 3 | Asthma | Jan 2027 |
| Candidate varicella vaccine Live attenuated varicella zoster virus vaccine | – | Phase 3 | Chickenpox | Feb 2027 |
| Cabotegravir Human immunodeficiency virus type 1 integrase inhibitor | INSTI, INTEGRASE | Phase 3 | HIV Infections; Infection, Human Immunodeficiency Virus; Pre-exposure Prophylaxis; HIV-1 Infected Adults With Controlled Viremia … | Mar 2027 |
| Camlipixant (BLU-5937) P2X purinoceptor 3 antagonist | P2RX3 | Phase 3 | Refractory Chronic Cough; Irritable Bowel Syndrome | Mar 2027 |
| Dolutegravir Human immunodeficiency virus type 1 integrase inhibitor | INSTI, RTASE, INTEGRASE, RT | Phase 3 | HIV; HIV Infections; HIV-1-infection; Acute HIV Infection … | Mar 2027 |
| Lamivudine Human immunodeficiency virus type 1 reverse transcriptase inhibitor; DNA polymerase/reverse transcriptase inhibitor | RT | Phase 3 | HIV; HIV Infection; HIV Prevention; Pre-exposure Prophylaxis … | Mar 2027 |
| GSK5784283 (Felcorekibart) | – | Phase 3 | Asthma; Nasal Polyps; Pulmonary Disease, Chronic Obstructive | Apr 2027 |
| Tafenoquine (TQ) 8-aminoquinoline antimalarial with activity against hypnozoites | – | Phase 3 | Malaria, Vivax | May 2027 |
| Mocertatug Rezetecan (Mo-Rez) TROP2-directed antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload | TROP2 | Phase 3 | Neoplasms, Endometrial; Ovarian Neoplasms; Tumours, Gynecological; Solid Tumors | Jun 2027 |
| mRNA Seasonal Flu vaccine mRNA vaccine encoding influenza antigens | – | Phase 3 | Influenza, Human | Jul 2027 |
| Risvutatug Rezetecan (GSK5764227) anti-B7-H3 antibody-drug conjugate | TROP2, CD276 | Phase 3 | Neoplasms, Lung; Neoplasms, Prostate; Neoplasms; Gastrointestinal Neoplasms | Aug 2027 |
| Efimosfermin alfa FGF21 analog | FGF21 | Phase 3 | Non-alcoholic Fatty Liver Disease; Metabolic Dysfunction-associated Steatohepatitis; Liver Diseases, Alcoholic | Oct 2027 |
| IDRX-42 (GSK6042981, velzatinib) Receptor tyrosine kinase inhibitor | KIT, PDGFRA | Phase 3 | Gastrointestinal Neoplasms; Gastrointestinal Stromal Neoplasms | Nov 2027 |
| MMRVNS Live attenuated vaccine against measles, mumps, rubella, and varicella | – | Phase 3 | Measles | Feb 2028 |
| Rilpivirine Human immunodeficiency virus type 1 reverse transcriptase inhibitor | RT | Phase 3 | HIV Infections; Infection, Human Immunodeficiency Virus; HIV-1 Infected Adults With Controlled Viremia; HIV -1 Infection … | Jun 2028 |
| CAB ULA Integrase strand transfer inhibitor (ultra-long-acting formulation) | INSTI | Phase 3 | HIV Infections | Sep 2029 |
| RPV ULA Non-nucleoside reverse transcriptase inhibitor (ultra-long-acting formulation) | POLR2A | Phase 3 | HIV Infections | Sep 2029 |
| Linerixibat Ileal bile acid transporter inhibitor | SLC10A2 | Phase 3 | Cholestasis | – |
| Nelistotug TIGIT inhibitor | – | Phase 2 | Lung Cancer, Non-Small Cell; Neoplasms, Head and Neck | Nov 2026 |
| Momelotinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Activin receptor type-1 inhibitor | JAK1, JAK2, ACVR1 | Phase 2 | Primary Myelofibrosis; Myelodysplastic Syndromes; VEXAS Syndome; Myeloid Leukemia … | Dec 2026 |
| GSK3862995B | – | Phase 2 | Bronchiectasis; Pulmonary Disease, Chronic Obstructive | Dec 2026 |
| Cobolimab Hepatitis A virus cellular receptor 2 inhibitor | HAVCR2 | Phase 2 | Lung Cancer, Non-Small Cell; Melanoma; Neoplasms; Cervical Cancer … | Dec 2026 |
| Adjuvanted RSVPreF3 vaccine RSV PreF3 protein subunit vaccine with adjuvant | RSV | Phase 2 | Respiratory Syncytial Virus Infections | Jan 2027 |
| VH3810109 CD4-targeting monoclonal antibody for HIV latency reversal and viral reservoir reduction | – | Phase 2 | HIV Infections | Jan 2027 |
| MenABCWY vaccine (GSK3536819A) Combination meningococcal vaccine against serogroups A, B, C, W, and Y | – | Phase 2 | Meningitis, Meningococcal | Mar 2027 |
| Bepirovirsen Antisense oligonucleotide targeting hepatitis B virus RNA | HBV | Phase 2 | Hepatitis B; Chronic Hepatitis B Virus Infection | Apr 2027 |
| RTS,S/AS01E vaccine recombinant malaria vaccine targeting circumsporozoite protein | – | Phase 2 | Malaria | Apr 2027 |
| Daplusiran/Tomligisiran RNAi therapeutic targeting hepatitis B virus and host factors | HBV | Phase 2 | Chronic Hepatitis B Virus Infection | May 2027 |
| VH4524184 HIV integrase inhibitor | – | Phase 2 | HIV Infections | Jun 2027 |
| Remzistotug | – | Phase 2 | Neoplasms, Head and Neck; Neoplasms | Aug 2027 |
| GSK4532990 | – | Phase 2 | Nonalcoholic Fatty Liver Disease; Liver Diseases, Alcoholic | Nov 2027 |
| iNTS-TCV Invasive nontyphoidal Salmonella-typhoid conjugate vaccine | – | Phase 2 | Salmonella Infections | Apr 2028 |
| Efimosfermin (BOS-580) FGF21 receptor agonist | FGF21R | Phase 2 | Metabolic Dysfunction-Associated Steatohepatitis | Jul 2028 |
| GSK4527226 | – | Phase 2 | Alzheimer's Disease | Sep 2028 |
| altSonflex1-2-3 Shigella vaccine | – | Phase 2 | Diarrhoea | Oct 2028 |
| Ganfeborole (GSK3036656) | – | Phase 1 | Tuberculosis; Pulmonary Tuberculosis | Nov 2026 |
| Pn-MAPS30plus Pneumococcal polysaccharide vaccine with enhanced immunogenicity formulation | – | Phase 1 | Pneumonia, Bacterial | Nov 2026 |
| Flu/COVm Vaccine mRNA vaccine encoding seasonal influenza and COVID-19 antigens | – | Phase 1 | Influenza, Human+COVID-19 | Dec 2026 |
| GSK6097608 | – | Phase 1 | Neoplasms | Dec 2026 |
| Feladilimab Inducible T-cell costimulator agonist | ICOS | Phase 1 | Multiple Myeloma | Mar 2027 |
| GSK4528287 | – | Phase 1 | Colitis, Ulcerative | Mar 2027 |
| Gsk-3174998 (GSK3174998) Tumor necrosis factor receptor superfamily member 4 agonist | TNFRSF4 | Phase 1 | Multiple Myeloma | Mar 2027 |
| Isatuximab Lymphocyte differentiation antigen CD38 inhibitor | CD38 | Phase 1 | Multiple Myeloma; Newly Diagnosed Multiple Myeloma; Relapsed Refractory Multiple Myeloma (RRMM); Recurrent Multiple Myeloma … | Mar 2027 |
| Nirogacestat Gamma-secretase inhibitor | APH1A, PSENEN, APH1B, PSEN1, NCSTN | Phase 1 | Multiple Myeloma; Tumor; Desmoid Tumor; AIDS-Related Kaposi Sarcoma | Mar 2027 |
| PED-HZ/su Recombinant zoster vaccine | – | Phase 1 | Herpes Zoster | Mar 2027 |
| Albuterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 1 | Asthma; TTN; Lymphangioleiomyomatosis | Apr 2027 |
| VH4770359 Antiretroviral compound | – | Phase 1 | HIV Infections | May 2027 |
| Gepotidacin Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor | TOPO2A | Phase 1 | Urinary Tract Infections | May 2027 |
| GSK4771261 | – | Phase 1 | Kidney Disease | May 2027 |
| Candidate UTI vaccine medium dose formulation 1 UTI vaccine | – | Phase 1 | Urinary Tract Infections | May 2027 |
| GSK 4-component Strep A Vaccine with Aluminum Hydroxide (Alum) Streptococcus pyogenes vaccine with aluminum hydroxide adjuvant | – | Phase 1 | Streptococcal Infections | Jun 2027 |
| GSK5458514 | – | Phase 1 | Neoplasms, Prostate | Oct 2027 |
| Risvutatug Rezetecan (Ris-Rez) | – | Phase 1 | Sarcoma; Neoplasms | Nov 2027 |
| Pan-Salmonella-with-Alum vaccine (Low dose) Quadrivalent Pan-Salmonella vaccine with alum adjuvant | – | Phase 1 | Salmonella Infections | Nov 2027 |
| GSK4527363 | – | Phase 1 | Systemic Lupus Erythematosus | Jan 2028 |
| Aletekitug (GSK1070806) Anti-IL-18 monoclonal antibody | IL18 | Phase 1 | Colitis, Ulcerative | Mar 2028 |
| GSK5926371 | – | Phase 1 | Systemic Lupus Erythematosus; Lymphoma, Non-Hodgkin | Mar 2028 |
| GSK5471713 | – | Phase 1 | Neoplasms, Prostate | Mar 2028 |
| GSK4425689A monoclonal antibody | – | Phase 1 | Malaria, Falciparum | Apr 2028 |
| VH4011499 | – | Phase 1 | HIV Infections | Aug 2028 |
| GSK5460025 | – | Phase 1 | Neoplasms, Colorectal | Sep 2028 |
| VH4367310 Cabotegravir prodrug | INSTI | Phase 1 | HIV Infections | Dec 2028 |
| GSK5533524 | – | Phase 1 | Neoplasms | Feb 2029 |
| RSV/hMPV_V high dose vaccine RSV and hMPV combination vaccine | – | Phase 1 | Respiratory Syncytial Virus Infections+Metapneumovirus | Apr 2029 |
| RSV/hMPV_V low dose vaccine RSV and hMPV combination vaccine | – | Phase 1 | Respiratory Syncytial Virus Infections+Metapneumovirus | Apr 2029 |
| RSV/hMPV_V medium dose vaccine RSV and hMPV combination vaccine | – | Phase 1 | Respiratory Syncytial Virus Infections+Metapneumovirus | Apr 2029 |
| RSV/hMPV_W low dose vaccine RSV and hMPV combination vaccine | – | Phase 1 | Respiratory Syncytial Virus Infections+Metapneumovirus | Apr 2029 |
| Ivonescimab PD-L2 inhibitor | PDCD1LG2 | Phase 1 | Neoplasms, Lung | Jun 2029 |
| GSK4418959 | – | Phase 1 | Neoplasms, Colorectal | – |
| GSK4524101 | – | Phase 1 | Neoplasms | – |
| VH4527079 Human monoclonal antibody | – | Phase 1 | HIV Infections | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02362503 | Fostemsavir | Phase 3 | HIV Infections | Infectious disease | Aug 2016 |
| NCT03164564 | Cabotegravir | Phase 3 | HIV Infections | Infectious disease | Nov 2020 |
| NCT03164564 | Cabotegravir | Phase 3 | HIV Infections | Infectious disease | Nov 2020 |
| NCT04651777 | FF/UMEC/VI | Phase 3 | Asthma | Respiratory | Aug 2023 |
| NCT04915755 | Niraparib | Phase 3 | Neoplasms, Breast | Oncology | Jun 2024 |
| NCT05598814 | Mepolizumab | Phase 4 | Chronic Rhinosinusitis with Nasal Polyps | Respiratory | Aug 2024 |
| NCT04802356 | Belantamab mafodotin | Phase 2 | Multiple Myeloma | Oncology | Mar 2025 |
| NCT05575830 | Varicella Zoster Virus Envelope Glycoprotein E | Phase 4 | RZV Vaccine (Shingrix ®) | Vaccines | Apr 2025 |
| NCT05122767 | Dolutegravir | Phase 1 | Tuberculosis | Infectious disease | Jul 2025 |
| NCT06970223 | Cabotegravir | Phase 1 | HIV Infections | Infectious disease | Jul 2025 |
| NCT06519357 | Lamivudine | Phase 2 | Mild Cognitive Impairment | Neurology | Sep 2025 |
| NCT05870761 | Dostarlimab | Phase 2 | Recurrent Endometrial Serous Adenocarcinoma | Oncology | Sep 2025 |
| NCT04337450 | Dolutegravir | Phase 2 | HIV Infections | Infectious disease | Sep 2025 |
| NCT05527704 | Albuterol | Phase 3 | TTN | Respiratory | Nov 2025 |
| NCT07006246 | Lamivudine | Phase 4 | HIV Infection | Infectious disease | Nov 2025 |
| NCT05583344 | GSK4532990 | Phase 2 | Nonalcoholic Fatty Liver Disease | Gastroenterology | Jan 2026 |
| NCT05220358 | Fostemsavir | Phase 4 | HIV-1-infection | Infectious disease | Feb 2026 |
| NCT07168356 | Bepirovirsen | Phase 1 | Hepatitis B | Genitourinary | Mar 2026 |
| NCT05626777 | Mepolizumab | Phase 4 | Asthma | Respiratory | Mar 2026 |
| NCT05942222 | Mepolizumab | Phase 4 | Chronic Rhinosinusitis With Nasal Polyps | Respiratory | Apr 2026 |
| NCT06250504 | Cabotegravir | Phase 3 | HIV Infections | Infectious disease | Apr 2026 |
| NCT03104842 | Isatuximab | Phase 2 | Multiple Myeloma | Oncology | May 2026 |
| NCT06710847 | GSK4418959 | Phase 1 | Neoplasms, Colorectal | Oncology | Jun 2026 |
| NCT06077877 | Niraparib | Phase 1 | Neoplasms | Oncology | Jun 2026 |
| NCT06077877 | GSK4524101 | Phase 1 | Neoplasms | Oncology | Jun 2026 |
| NCT06485154 | Lamivudine | Phase 4 | HIV Prevention | Infectious disease | Jun 2026 |
| NCT07636928 | VH4524184 | Phase 1 | HIV Infections | Infectious disease | Aug 2026 |
| NCT06652958 | VH4527079 | Phase 1 | HIV Infections | Infectious disease | Sep 2026 |
| NCT05263934 | Depemokimab | Phase 3 | Eosinophilic Granulomatosis With Polyangiitis | Immunology | Sep 2026 |
| NCT06534892 | RSVPreF3 OA investigational vaccine | Phase 3 | Respiratory Syncytial Virus Infections | Infectious disease | Sep 2026 |
| NCT04167358 | Linerixibat | Phase 3 | Cholestasis | Gastroenterology | Sep 2026 |
| NCT06521567 | Cobolimab | Phase 1 | Melanoma | Oncology | Oct 2026 |
| NCT06521567 | Dostarlimab | Phase 1 | Melanoma | Oncology | Oct 2026 |
| NCT05565378 | Dostarlimab | Phase 2 | Lung Cancer, Non-Small Cell | Oncology | Nov 2026 |
| NCT05565378 | Belrestotug | Phase 2 | Lung Cancer, Non-Small Cell | Oncology | Nov 2026 |
| NCT05565378 | Nelistotug | Phase 2 | Lung Cancer, Non-Small Cell | Oncology | Nov 2026 |
| NCT05338190 | Belimumab | Phase 3 | Primary Immune Thrombocytopenia (ITP) | Hematology | Nov 2026 |
| NCT05526989 | Dostarlimab | Phase 2 | Penile Carcinoma | Oncology | Nov 2026 |
| NCT06517017 | Isatuximab | Phase 2 | Multiple Myeloma | Oncology | Nov 2026 |
| NCT07784894 | Ganfeborole (GSK3036656) | Phase 1 | Tuberculosis | Infectious disease | Nov 2026 |
| NCT07428759 | Pn-MAPS30plus | Phase 1 | Pneumonia, Bacterial | Infectious disease | Nov 2026 |
| NCT06567782 | Dostarlimab | Phase 2 | Neoplasms, Colon | Oncology | Nov 2026 |
| NCT07596199 | dTpa vaccine (Boostrix) | Phase 3 | Diphtheria-Tetanus-acellular Pertussis Vaccines | Vaccines | Nov 2026 |
| NCT06693895 | Investigational varicella vaccine (VNS Vaccine) | Phase 3 | Chickenpox | Infectious disease | Nov 2026 |
| NCT04165772 | Dostarlimab | Phase 2 | Rectal Adenocarcinoma | Oncology | Nov 2026 |
| NCT04892654 | Dolutegravir | Phase 3 | HIV-1-infection | Infectious disease | Nov 2026 |
| NCT07133880 | Umeclidinium | Phase 4 | COPD (Chronic Obstructive Pulmonary Disease) | Respiratory | Dec 2026 |
| NCT06238635 | Cobolimab | Phase 2 | Cervical Cancer | Oncology | Dec 2026 |
| NCT06238635 | Dostarlimab | Phase 2 | Cervical Cancer | Oncology | Dec 2026 |
| NCT06832865 | Isatuximab | Phase 2 | Relapsed Refractory Multiple Myeloma (RRMM) | Oncology | Dec 2026 |
| NCT07464314 | Flu/COVm Vaccine | Phase 1 | Influenza, Human+COVID-19 | Infectious disease | Dec 2026 |
| NCT03441113 | Momelotinib | Phase 2 | Primary Myelofibrosis | Oncology | Dec 2026 |
| NCT06317311 | Dostarlimab | Phase 2 | Carcinoma | Oncology | Dec 2026 |
| NCT06806137 | Investigational varicella vaccine (VNS Vaccine) | Phase 3 | Chickenpox | Infectious disease | Dec 2026 |
| NCT06158126 | Cabotegravir | Phase 4 | Pre-exposure Prophylaxis | Infectious disease | Dec 2026 |
| NCT05002816 | Belantamab mafodotin | Phase 1 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT04403139 | Varicella Zoster Virus Envelope Glycoprotein E | Phase 4 | Varicella Zoster Virus Infection | Infectious disease | Dec 2026 |
| NCT03016338 | Dostarlimab | Phase 2 | Endometrial Cancer | Oncology | Dec 2026 |
| NCT04068753 | Dostarlimab | Phase 2 | Recurrent Cervix Cancer | Oncology | Dec 2026 |
| NCT06967753 | Dolutegravir | Phase 4 | HIV | Infectious disease | Dec 2026 |
The 60 nearest readouts of 397 trials; the rest in the app.
Cash of 3.4bn GBP on 2025-12-31; operating cash flow positive
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
INSTI (5) RT (3) INTEGRASE (2) TROP2 (2) IL5 (2) HBV (2) CHRM3 (2) ADRB2 (2) TNFRSF17 (1) Tubulin (1) TNFRSF4 (1) ICOS (1)
Gilead Sciences Merck & Co. (MSD) Sichuan Baili Pharmaceutical Astellas Beijing Biotech Akeso MacroGenics OBI Pharma Mabwell (Shanghai) Bioscience Bio-Thera Solutions
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.